Conflicts of interest have kept Lars Rebien Sørensen away from pharmaceutical boards – until now

Up until now, Lars Rebien Sørensen has refrained from taking on board roles at pharmaceutical companies due to the risk of conflicts of interest. Now, the chairman of the Novo Nordisk Foundation will be taking on the role of chairman of the board at Ferring, although he highlights one possible conflict of interest with Denmark's largest pharmaceutical giant.
Lars Rebien Sørensen, chairman of the board of directors at Novo Nordisk Fonden and Ferring Pharmaceuticals
Lars Rebien Sørensen, chairman of the board of directors at Novo Nordisk Fonden and Ferring Pharmaceuticals
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN

As the future chairman of Ferring Pharmaceuticals, Lars Rebien Sørensen will soon be taking on his first board role within the pharmaceutical industry.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading